Literature DB >> 6641087

Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers.

M S Lennard, G T Tucker, J H Silas, S Freestone, L E Ramsay, H F Woods.   

Abstract

The hypothesis that variability in metoprolol metabolism stereoselectivity is related to debrisoquin oxidation phenotype was tested in six extensive (EM) and six poor (PM) debrisoquin metabolizers. In EM, plasma AUCs for (S)-metoprolol were 35% higher than for (R)-metoprolol, whereas in PM, AUCs for (S)-metoprolol were lower than for (R)-metoprolol. AUCs for total metoprolol correlated with the ratio of (S)- to (R)-metoprolol AUC. The renal clearance of metoprolol was also stereoselective but to the same extent in both EM and PM. Findings suggest that the enzyme system responsible for polymorphic oxidation of the debrisoquin-type is stereoselective. The relation between log total metoprolol plasma concentration and response (beta-blockade) was shifted to the right in PM relative to EM, which is compatible with a difference in pharmacologic activity of metoprolol enantiomers. Kinetic predictions based on total drug measurements will tend to overestimate dynamic differences between EM and PM, but the magnitude of the error is relatively small, and, in absolute terms, there is a large difference in pharmacologic activity between the phenotypes (beta-blockade at 24 hr: EM = 5.3 +/- 5.6%; PM = 18.9 +/- 3.8%).

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6641087     DOI: 10.1038/clpt.1983.242

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  60 in total

1.  Influence of stereoselective pharmacokinetics in the development and predictability of an IVIVC for the enantiomers of metoprolol tartrate.

Authors:  N Sirisuth; N D Eddington
Journal:  Pharm Res       Date:  2000-08       Impact factor: 4.200

Review 2.  Impact of stereoselectivity on the pharmacokinetics and pharmacodynamics of antiarrhythmic drugs.

Authors:  Reza Mehvar; Dion R Brocks; Majid Vakily
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 3.  Stereoselectivity in clinical pharmacokinetics and drug development.

Authors:  D B Campbell
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

4.  Lack of effect of omeprazole treatment on steady-state plasma levels of metoprolol.

Authors:  T Andersson; P Lundborg; C G Regårdh
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 5.  Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.

Authors:  Peer Tfelt-Hansen; Frederik Nybye Ågesen; Agniezka Pavbro; Jacob Tfelt-Hansen
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

Review 6.  Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping.

Authors:  D Frank; U Jaehde; U Fuhr
Journal:  Eur J Clin Pharmacol       Date:  2007-02-02       Impact factor: 2.953

7.  Polymorphic metabolism of metoprolol: clinical studies.

Authors:  J H Silas; J C McGourty; M S Lennard; G T Tucker; H F Woods
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.

Authors:  J C McGourty; J H Silas; M S Lennard; G T Tucker; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

9.  Pharmacokinetics and dynamics of penbutolol in humans: evidence for pathway-specific stereoselective clearance.

Authors:  H R Ochs; P Hajdú; D J Greenblatt
Journal:  Klin Wochenschr       Date:  1986-07-15

10.  Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype.

Authors:  A S Gross; G Mikus; C Fischer; R Hertrampf; U Gundert-Remy; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.